Atossa Therapeutics

ATOS · NASDAQ

$2.54−$0.02 (−0.78%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $2.56

ATOS analyst rating

BuyConsensus of 3 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy3
Hold0
Underperform0
Sell0

12-month price target · 5 analysts

Average $19.38 (+663.0% upside)

Low: $10.10
Now: $2.54
High: $26.25

Upgrades and downgrades

The latest rating actions, newest first

ATOS analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Ascendiant Capital	Oct 1, 2026	Maintains	Buy	$24.00 → $25.00	28%
Rodman & Renshaw	Jul 7, 2026	Initiates	Buy	$12.00	40%
Ascendiant Capital	Apr 10, 2026	Maintains	Buy	$120.00 → $24.00	28%
HC Wainwright & Co.	Mar 26, 2026	Maintains	Buy	$7.00 → $25.00	27%
Ascendiant Capital	Dec 8, 2025	Maintains	Buy	$7.75 → $8.00	28%

The case for and against

Updated May 26, 2026

Bull case

Atossa Therapeutics is a clinical-stage biopharmaceutical company with a positive outlook due to 5 clinical trials currently in progress, a successful 15-for-1 reverse stock split that has increased its market potential, the appointment of a new CFO with extensive experience in the global life-science industry, and the company's progress in developing Endoxifen for multiple breast-cancer indications. Despite the long development timeline and risks associated with clinical trials, the billion-dollar market potential presents a promising investment opportunity. However, risks to attainment of the company's share price target include balance sheet and liquidity risks, difficulty in obtaining regulatory approvals and suitable reimbursement, competition, and changing macroeconomic factors.

Bear case

Atossa Therapeutics is currently operating at a loss and has no revenue. As a clinical-stage company, their drugs are still in development and face high risks of failure in clinical trials. However, with a potential market worth billions, the potential rewards outweigh the risks in the long term.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.